Clinical trials: Upper Respiratory Infection
Respiratory Syncytial Virus Infections
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
The purpose of this study is: To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately…
- Trial name
- RSV OA=ADJ=012 (NCT06534892)
- Testing
- RSVPreF3 OA vaccine
- Where
- 251 sites in United States, Australia and 15 more
- Volunteers
- 10,212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lymphoceles Following Pelvic Lymph Node Dissection
Cold Plasma for the Reduction of Lymphoceles Following PLND
This study protocol will evaluate the efficacy of Bovie Medical's J-Plasma® helium based plasma technology in the reduction of lymphoceles following pelvic lymph node dissection (PLND) during robotic assisted radical…
- Trial name
- NCT02658851
- Testing
- J-Plasma
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Apyx Medical
Osteoarthritis, Total Knee Arthroplasty
Use of Cold and Compression Therapy With Total Knee Replacement Patients
The purpose of the study is to evaluate the effectiveness of a device that delivers cold and intermittent compression as compared to ice and compressive wraps on patients who have undergone knee replacement.
- Trial name
- NCT00712816
- Testing
- Game Ready Injury Treatment System (CoolSystems Inc.), Ice with compressive bandages
- Where
- 11 sites in United States, Australia
- Volunteers
- 224 people
- Sponsor
- CoolSystems, Inc.
Pneumonia, Pneumococcal
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
- Trial name
- NCT04278248
- Testing
- 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,940 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Upper Respiratory Tract Infections, Pharyngitis
Efficacy and Safety of L. Plantarum and P. Acidilactici in Children With Upper Respiratory Tract Infections
Randomized, placebo-controlled trial to evaluate the coadjuvant effect of a combination of L. plantarum and P. acidilactici probiotic strains, taken twice daily, in children 6 months to 5 years-old with upper respiratory tract…
- Conditions
- Upper Respiratory Tract Infections, Pharyngitis, Tonsillitis
- Trial name
- NCT05279534
- Testing
- Probiotic
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- AB Biotics, SA
Bronchiolitis
Nebulized 5% Hypertonic Saline for the Treatment of Bronchiolitis
The investigators reasoned that a hypertonic saline concentration higher than 3% could be safe and more efficacious in the treatment of bronchiolitis, alleviating severe symptoms and preventing the need for hospitalization in…
- Trial name
- NCT01016249
- Testing
- Treatment 1. (5% Hypertonic saline + Epinephrine), Treatment 3. (3% Hypertonic saline + Epinephrine), Treatment 2. (Normal saline + Epinephrine)
- Where
- Qatar
- Volunteers
- 187 people
- Sponsor
- Hamad Medical Corporation
Influenza
Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza
To demonstrate that the efficacy over a defined surveillance period against culture-confirmed influenza-illness caused by community-acquired subtypes antigenically similar to those contained in the vaccine, in adults aged at…
- Trial name
- FluMist (NCT00192413)
- Testing
- Cold-adapted influenza vaccine trivalent (CAIV-T), Trivalent Inactivated Vaccine (TIV)
- Where
- 4 sites in South Africa
- Volunteers
- 3,009 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Infection
Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections
The objectives of this study are: a) to assess the feasibility and sensitivity of manually count cough bouts over a 4-hour period; b) to assess the effects of buckwheat honey and guaifenesin 400 mg immediate release tablets…
- Trial name
- NCT01062256
- Testing
- Guaifenesin, Buckwheat Honey
- Where
- 2 sites in United States
- Volunteers
- 265 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Herpes Labialis, Cold Sore
Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis
This study evaluates the safety and efficacy of SADBE in the prevention of recurrent herpes labialis in adults. Two-thirds of the participants will receive a SADBE solution, while the other third will receive only the vehicle as…
- Trial name
- P2a (NCT02965781)
- Testing
- SADBE
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Squarex, LLC
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older
The purpose of this study is to assess, in adults 18 years of age and above, the immunogenicity and reactogenicity of the seasonal influenza vaccine, Fluarix/Influsplit SSW 2013/2014, containing the three vaccine influenza…
- Trial name
- NCT01884519
- Testing
- Fluarix/Influsplit SSW® (2013-2014 season)
- Where
- 4 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dry Eye Disease
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
The purpose of this study is to evaluate the safety of topical ophthalmic 0.003% AR-15512 compared to its vehicle dosed twice daily (BID) in subjects with dry eye disease (DED) for 12 months.
- Trial name
- COMET-4 (NCT05493111)
- Testing
- 0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
- Where
- 10 sites in United States
- Volunteers
- 275 people
- Sponsor
- Aerie Pharmaceuticals
Influenza, Human
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and…
- Trial name
- NCT07204964
- Testing
- Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A)
- Where
- 17 sites in United States, Belgium
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
- Trial name
- NCT00378521
- Testing
- MQX-503
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
Influenza, Viral Respiratory Infection
A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
A multicenter, randomized, double-blind, placebo controlled comparative study to evaluate the safety, tolerability and efficacy of XC221 used at 100 mg daily and at 200 mg daily in patients with uncomplicated influenza or other…
- Conditions
- Influenza, Viral Respiratory Infection, Acute Viral Upper Respiratory Infections
- Trial name
- NCT05030324
- Testing
- XC221 100 mg, XC221 200 mg
- Where
- 9 sites in Russia
- Volunteers
- 255 people
- Sponsor
- Valenta Pharm JSC
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
The aim of the study is to assess the safety of inhaled SNG001 and the ability of inhaled SNG001 to 'switch on' the cells' anti-viral defences in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03570359
- Testing
- Interferon Beta-1A
- Where
- 16 sites in United Kingdom
- Volunteers
- 122 people
- Sponsor
- Synairgen Research Ltd.
Healthy Volunteers
A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study
The study design of this trial is a Dose-Block Randomized, Placebo controlled (Double-blind), Active Controlled(Open-label), Dose-escalation.
- Trial name
- NCT02175056
- Testing
- HL2351, Kineret(Anakinra)
- Where
- South Korea
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
COVID-19
Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and immunogenicity of ZR-202-CoV, administered as 2 injections (i.m) at 28 days apart in adult subjects 60 years of age and above.
- Trial name
- NCT05313022
- Testing
- ZR-202-CoV
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Common Cold
Efficacy and Safety of Irlanda-1-Association on the Treatment of Common Cold in Children
The purpose of this study is to evaluate the clinical efficacy of the drug associations in the treatment of common cold symptoms.
- Trial name
- NCT02656888
- Testing
- Irlanda-1-Association
- Where
- Brazil
- Sponsor
- EMS
Common Cold
Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold
The aim of this study is to characterize the time profile of the decongestant properties of xylometazoline and to investigate its effect on sleep, general well-being and smell/taste.
- Trial name
- NCT00452270
- Testing
- Xylometazoline
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Novartis
Upper Respiratory Tract Infections
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
Acute respiratory tract infections (ARTIs), such as acute rhinosinusitis (ARS) and acute otitis media (AOM), are common worldwide and caused by viruses or bacteria entering the body through the mouth and nose.
- Trial name
- NCT05804123
- Testing
- 0.9% NaCl physiological saline Nasal-spraying, LiveSpo Navax®, Augmentin 500Mg Tablet
- Where
- Vietnam
- Volunteers
- 175 people
- Sponsor
- Anabio R&D